Featured Research

from universities, journals, and other organizations

Diabetes Drug Class Linked To Vision-Threatening Complication

Date:
April 13, 2009
Source:
Elsevier
Summary:
Patients taking glitazones at increased risk of diabetic macular edema, suggests a new study.

Treatment with the glitazone class of diabetes drugs leads to a "modest" increase in the risk of diabetic macular edema (DME)—a common complication that can lead to vision loss, reports a study in the April issue of the American Journal of Ophthalmology.

Related Articles


Using a database of about 170,000 patients with diabetes, Drs. Donald S. Fong and Richard Contreras of Southern California Permanente Medical Group analyzed the link between glitazones and the development of DME.  Diabetic macular edema is a common diabetes complication, with swelling and fluid build-up in the retina leading to progressive visual loss.

The researchers identified 996 patients who were diagnosed with DME during 2006.  Overall, patients who took glitazones were 2.6 times more likely to develop DME than patients not taking these drugs.  Even after further adjustment for other factors, DME risk remained 60 percent higher for glitazone users.

Previous studies have linked glitazones to problems related to fluid retention and edema (swelling), including heart failure.  Fluid retention from heart failure or other diseases can worsen DME.  Most of the glitazone users in the study were taking pioglitazone (Actos).  Other studies have linked rosiglitazone (Avandia)—the only other approved glitazone drug—to a possible increase in the risk of myocardial infarction.

Although the study is not the first to suggest a link, it provides confirmation in a very large sample of diabetic patients that glitazones are "modestly associated" with DME.  Drs. Fong and Contreras concluded, "When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs."

"Ocular complications are an overlooked safety issue of systemic drugs,” commented Dr. Thomas J. Liesegang, Editor-in-Chief of AJO, "Safety is as important as the efficacy of a drug.  However, long term safety is not currently monitored because the approval process is based on smaller, shorter term clinical trials.  Safety necessarily requires monitoring of treatment in larger groups of people over longer periods of time.  This monitoring is often neglected and should be required of all therapies."


Story Source:

The above story is based on materials provided by Elsevier. Note: Materials may be edited for content and length.


Cite This Page:

Elsevier. "Diabetes Drug Class Linked To Vision-Threatening Complication." ScienceDaily. ScienceDaily, 13 April 2009. <www.sciencedaily.com/releases/2009/04/090402092855.htm>.
Elsevier. (2009, April 13). Diabetes Drug Class Linked To Vision-Threatening Complication. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2009/04/090402092855.htm
Elsevier. "Diabetes Drug Class Linked To Vision-Threatening Complication." ScienceDaily. www.sciencedaily.com/releases/2009/04/090402092855.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins